Loading... Please wait... Loading... Please wait...
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
The biotech industry has fallen on hard times over the last few years, no thanks to venture capital drying up, tighter regulatory conditions and the harsh reality of the post-pandemic healthcare envir...
Amazon (NASDAQ: AMZN ) has more skin in the AI game than many people would like to think. Of course, the first thing that would spring to mind is the company's AWS cloud division....
With the progression of modern medicine, and the continuous discoveries in the realm of gene editing, investing early in the technology could be a game changer for long-term returns if selecting the b...
Beam Therapeutics (BEAM) doses the first patient in a phase I/II study, evaluating in vivo base editor BEAM-302 for treating alpha-1 antitrypsin deficiency....
CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the firs...
MADRID, June 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported data highlighting i...
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock?...
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Gius...
National Bank of Canada FI boosted its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 200.0% during the 4th quarter, according to the company in its most recent disc...
